



## **Aptinyx to Present NYX-2925 Research at American Pain Society Annual Scientific Meeting**

**Evanston, Ill., May 17, 2017** – Aptinyx Inc., a biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced it will present at the American Pain Society’s Annual Scientific Meeting, May 17-20, 2017 in Pittsburgh, PA. The presentation will feature results from preclinical studies that further elucidate the mechanism of action of the company’s lead product candidate, NYX-2925, a novel modulator of the N-methyl-D-aspartate (NMDA) receptor, in neuropathic pain.

“Multiple *in vivo* models continue to reveal the mechanism by which NYX-2925 drives its effects on the central nervous system,” said Joseph Moskal, Ph.D., chief scientific officer of Aptinyx. “Compelling data from these studies support development of NYX-2925 as a potential treatment for neurologic disorders, including neuropathic pain associated with diabetic peripheral neuropathy.”

### **Presentation Details**

#### **NYX-2925, a Novel NMDA Receptor Modulator, Shows Efficacy in Neuropathic Pain that Is NMDA and AMPA Receptor Dependent and Appears to Be Driven through Brain, but NOT Spinal Circuitry (Poster #198)**

**Presenter:** Nayereh Ghoreishi-Haack, Ph.D., Aptinyx

**Presentation Time:** Author attended poster session Thursday, May 18, 3:45 to 5:15 p.m. EST

**Abstract Available:** [The Journal of Pain](#), Vol. 18, Issue 4, S25. Published April 2017.

**Summary:** *In vivo* injury models in the rat were utilized to evaluate the mechanism of action of NYX-2925 in pain conditions. The results demonstrate the analgesic effect of NYX-2925 is reliant on both NMDA and AMPA receptors, is brain – but not spinal – mediated, and is specific to neuropathic but not nociceptive pain conditions.

Discovered internally by Aptinyx scientists, NYX-2925 is an oral, small-molecule NMDA receptor modulator arising from the company’s proprietary chemistry platform. The U.S. Food and Drug Administration has granted Fast Track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Results from a randomized, double-blind, placebo-controlled, Phase 1 study of NYX-2925 in healthy volunteers are expected to be reported next month.

### **About Aptinyx**

Aptinyx Inc. is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural

cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism of modulating NMDA receptors, resulting in drugs that are both highly effective and well tolerated. This mechanism has applicability across a number of disorders of the brain and nervous system. For more information, visit [www.aptinyx.com](http://www.aptinyx.com).

# # # #

**Company Contact:**

Ashish Khanna  
Chief Business Officer  
Aptinyx Inc.  
[corporate@aptinyx.com](mailto:corporate@aptinyx.com)  
847-871-0377

**Media Contact:**

Ian Stone  
Canale Communications  
[ian@canalecomm.com](mailto:ian@canalecomm.com)  
619-849-5388